Oncolytics Biotech arranges $20 million at-the-market sales agreement

Agent Canaccord Genuity helps fund general corporate purposes for 3%

By Devika Patel

Knoxville, Tenn., Oct. 24 – Oncolytics Biotech Inc. could raise up to $20 million through an at-the-market sales agreement, according to a prospectus supplement filed Friday with the Securities and Exchange Commission.

Canaccord Genuity Inc. is the agent and will be paid a 3% commission.

Proceeds will be used for general corporate purposes.

Oncolytics is a biotechnology company based in Calgary, Alta. Its shares trade on the Nasdaq, under the symbol “ONCY.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.